A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer

A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07446387 by Jiangsu Cancer Institute & Hospital, with 70 participants planned, started 2026-05-30 and due to reach its primary completion in 2028-12-31. Interventions recorded: Iparomlimab and tuvonralimab. Conditions recorded: Metastatic Colorectal Cancer (CRC).

Linked to the drug Iparomlimab and tuvonralimab because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.